EcoDrugPlus

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSSCAG00000005327
Gene Symbol: MLST8
1 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nadph Oxidase 4

Ensembl ID : ENSSCAG00000003176
Gene Symbol: NOX4
3 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSSCAG00000016126
Gene Symbol: NFE2L2
1 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSCAG00000004052
Gene Symbol: PIM3
1 Cross references
217 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSSCAG00000014691
Gene Symbol: ROS1
3 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSCAG00000011068
Gene Symbol: RAF1
3 Cross references
221 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSSCAG00000010251
Gene Symbol: ROCK1
3 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSSCAG00000012610
Gene Symbol: ROCK2
3 Cross references
303 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sem1 26s Proteasome Subunit

Ensembl ID : ENSSCAG00000013093
Gene Symbol: SEM1
1 Cross references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSCAG00000012544
Gene Symbol: SRC
3 Cross references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSSCAG00000011019
Gene Symbol: TEK
3 Cross references
163 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ttk Protein Kinase

Ensembl ID : ENSSCAG00000004607
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).